New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›State Street Investment Management›XBI

XBI

State Street SPDR S&P Biotech ETF

Passive ETF Equity

The XBI Exchange Traded Fund (ETF) is provided by State Street Investment Management. It is built to track an index: S&P Biotechnology Select Industry Index. The XBI ETF provides physical exposure, so by buying it you actually own parts of all the 152 underlying holdings. This share class generates a stream of income by distributing dividends.

$154.84

+$4.4 (+2.90%) yesterday

1:30 PM 10/27/26 Closed

1D price range

$149.27$154.92

52W price range

$106.30$169.89

YTD Perf.

+27.02%

YTD Flows

Annualized volatility

Fund AuM

€9.29B

Share class AuM

€9.29B

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US78464A8707

TER

0.35%

Inception date

1/31/2006

Issuer

State Street Investment Management

Benchmark

S&P Biotechnology Select Industry Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
CURE Global X S&P Biotech ETF	+0.69%
XPH State Street SPDR S&P Pharmaceuticals ETF	-0.36%
PTH Invesco DWA Healthcare Momentum ETF	+2.29%
BBP Virtus LifeSci Biotech Products ETF	-0.79%
ARKG ARK Genomic Revolution ETF	+6.06%
PSCH Invesco S&P SmallCap Health Care ETF	+1.87%
AAKG ARK Genomic Revolution UCITS ETF	+5.79%
XHE State Street SPDR S&P Health Care Equipment ETF	+1.42%
SBIO ALPS Medical Breakthroughs ETF	+1.22%
BBC Virtus LifeSci Biotech Clinical Trials ETF	+0.48%
XHS State Street SPDR S&P Health Care Services ETF	+0.01%
IBRN iShares Neuroscience and Healthcare ETF	+1.29%
HELX Franklin Genomic Advancements ETF	+3.93%
FMED Fidelity Disruptive Medicine ETF	+2.21%
EKG First Trust Nasdaq Lux Digital Health Solutions ETF	+3.26%

API

PerformanceDec 31, 2025 - Oct 27, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 08/31/26

Healthcare

99.18%

Other

0.72%

Latest XBI news

No content available for this fund

FAQ about XBI

XBI is a passively managed ETF that invests in the US Health Care segment.

XBI tracks the S&P Biotechnology Select Industry Total Return Index - USD, through a full replication replication method.

XBI carries a total expense ratio (TER) of 0.35%.

XBI was introduced to the market on January 31, 2006.

State Street SPDR S&P Biotech ETF, XBI, is provided by State Street Investment Management. Learn more about State Street Investment Management here.

XBI oversees €9.29B in assets as of October 27, 2026.

XBI follows a distributing dividend policy, meaning it pays out income to investors. As of October 27, 2026, its 12-month trailing yield was 0.35%.

As of August 31, 2026, XBI has significant geographic allocations in USA, United Kingdom and Ireland.

As of August 31, 2026, XBI focuses largely on Healthcare.

As of August 31, 2026, XBI holds 152 positions in its portfolio, with 21.91% of assets concentrated in its top 15 holdings.

As of August 31, 2026, XBI top three holdings include Moderna, Inc., Twist Bioscience Corp. and Apogee Therapeutics, Inc..

The base currency of XBI is USD.

Top 10 holdings

Data as of 08/31/26

Moderna, Inc.

2.81%

Twist Bioscience Corp.

1.89%

Apogee Therapeutics, Inc.

1.50%

Kymera Therapeutics, Inc.

1.40%

Halozyme Therapeutics, Inc.

1.39%

Natera, Inc.

1.37%

Praxis Precision Medicines, Inc.

1.34%

Oruka Therapeutics, Inc.

1.33%

Revolution Medicines, Inc.

1.31%

Travere Therapeutics, Inc.

1.30%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

State Street SPDR S&P Biotech ETF

FAQ about XBI

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US